|
⚲
|
| Keyboard |
| CVF Management Group LLC
✚
|
|
|---|---|
| CRD # | 162830 |
| SEC # | 802-75461 |
| CIK # | 0001112278 |
| AUM | |
| Employees | |
| Phone | 607-227-1153 |
| Address | 15 Thornwood Drive Ithaca, NY 14850 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Cayuga Venture Fund V LP | [2016-03-24] | 15.6 M | 39.3 M |
| Filed 2012-05-16 (D/A) · Exemption 506, 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | CVF IV Innovate NY Fund LP | [2013-03-21] | 3.0 M | 2.4 M |
| Offered $10,000,000 · Filed 2009-07-10 (D) · Exemption 506, 3(c), 3(c)(1) · Minimum $50,000 · Remaining $7,005,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Cayuga Venture Fund III LP | 2012-03-29 | 1.6 M | |
| VC | Cayuga Venture Fund IV LP | [2012-03-29] | 15.6 M | 2.6 M |
| Filed 2012-05-16 (D/A) · Exemption 506, 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | CVF III Auxiliary Fund LP | [2012-03-29] | 3.0 M | 0.3 M |
| Offered $10,000,000 · Filed 2009-07-10 (D) · Exemption 506, 3(c), 3(c)(1) · Minimum $50,000 · Remaining $7,005,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Zachary Shulman | Executive Officer | 33 | 2 | |
| Philip Proujansky | Executive Officer | 13 | 2 | |
| Jennifer Tegan | Executive Officer | 10 | 2 | |
| Cliff Lardin | Executive Officer | 3 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001112278] | |
| 4 | [0001112278] | |
| SC 13G | [0001112278] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| CVF LLC | Fractyl Health Inc | [2024-02-14] |
| CVF LLC | Minerva Surgical Inc | [2022-02-10] |
| CVF LLC | Inari Medical Inc | [2020-11-20] |
| CVF LLC | Cerulean Pharma Inc | [2015-02-17] |
| CVF LLC | Genocea Biosciences Inc | [2015-02-17] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Fractyl Health Inc | |
| HCC Manager LLC | |
| CVF LLC | |
| Kala Bio Inc | |
| Rein Therapeutics Inc | |
| Dare Bioscience Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Fractyl Health Inc GUTS
Convertible Promissory Note · derivative
|
2024-02-06 | Conversion | 0 | ||
|
Fractyl Health Inc GUTS
Series F Preferred Stock · derivative
|
2024-02-06 | Conversion | 333,957 | ||
|
Fractyl Health Inc GUTS
Series E Preferred Stock · derivative
|
2024-02-06 | Conversion | 2,914,228 | ||
|
Fractyl Health Inc GUTS
Series D Preferred Stock · derivative
|
2024-02-06 | Conversion | 4,090,872 | ||
|
Fractyl Health Inc GUTS
Common Stock
|
2024-02-06 | Conversion | 3,419,876 | ||
|
Fractyl Health Inc GUTS
Common Stock
|
2024-02-06 | Conversion | 920,661 | ||
|
Fractyl Health Inc GUTS
Common Stock
|
2024-02-06 | Buy | 333,333 | $15.00 | 4,999,995 |
|
Rein Therapeutics Inc ALRN
Common Stock
|
2017-07-05 | Conversion | 536,180 | ||
|
Rein Therapeutics Inc ALRN
Common Stock
|
2017-07-05 | Buy | 180,000 | $15.00 | 2,700,000 |
|
Rein Therapeutics Inc ALRN
Series F Preferred Stock · derivative
|
2017-07-05 | Conversion | 916,262 | $0.00 | |
|
Rein Therapeutics Inc ALRN
Series E-3 Preferred Stock · derivative
|
2017-07-05 | Conversion | 4,411,765 | $0.00 | |
|
Dare Bioscience Inc CERU
Common Stock
|
2015-04-07 | Buy | 333,333 | $6.00 | 1,999,998 |
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Buy | 827,456 | $7.00 | 5,792,192 |
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 152,764 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 830,480 | ||
|
Dare Bioscience Inc CERU
Common Stock
|
2014-04-15 | Conversion | 448,544 | ||
|
Dare Bioscience Inc CERU
7% Convertible Promissory Note · derivative
|
2014-04-15 | Conversion | 828,746.78 | $0.00 | |
|
Dare Bioscience Inc CERU
7% Convertible Promissory Note · derivative
|
2014-04-15 | Conversion | 3,139,808.22 | $0.00 | |
|
Dare Bioscience Inc CERU
Series D Convertible Preferred · derivative
|
2014-04-15 | Conversion | 12,048,192 | $0.00 |